Welcome to our dedicated page for China Natural Resources news (Ticker: CHNR), a resource for investors and traders seeking the latest updates and insights on China Natural Resources stock.
China Natural Resources, Inc. operates as a British Virgin Islands holding company focused on exploration and mining. The company, through operating subsidiaries in the PRC, is engaged in the acquisition and exploitation of mining rights in Inner Mongolia, including exploration for lead, silver and other nonferrous metals at the Wulatehouqi Moruogu Tong Mine.
CHNR news commonly covers operating and financial results, exploration spending, mine-rights activity, capital-structure actions, shareholder matters, Nasdaq listing compliance, and governance updates. Company communications also address its review of opportunities in natural resources, healthcare, and other non-natural-resource sectors.
On April 27, 2022, China Natural Resources, Inc. (NASDAQ: CHNR) received notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive business days. The company has until October 24, 2022, to regain compliance, with the opportunity for a 180-day extension if necessary. Despite this notification, trading of CHNR shares continues uninterrupted on Nasdaq. The company is involved in wastewater treatment and mining rights in China.
China Natural Resources, Inc. (NASDAQ: CHNR) plans to enhance exploration and capital spending at its Moruogu Tong Mine in Inner Mongolia in 2022, focusing on nickel and gold anomalies. The company aims to fund six new drilling holes, with an initial investment of CNY2.16 million. Chairman Wong Wah On Edward emphasized the urgency of exploration amid high commodity prices and escalating demand, particularly for electric vehicles and electronics. Additionally, the company is assessing other resource opportunities to maximize asset value for shareholders.
On March 14, 2022, China Natural Resources secured an extension of its exploration permit for the Moruogu Tong mine in Inner Mongolia, extending until 2026. The Company anticipates potential copper discovery which could enhance asset valuation. Due to escalating raw material costs and supply shortages, capital expenditures will increase to support exploration and pre-mining programs in 2022. Chairman Wong Wah On Edward highlighted the urgency for exploration amid global demand pressures, indicating that discovery and extraction of minerals will be pivotal for maximizing shareholder value.
China Natural Resources (NASDAQ: CHNR) reported its unaudited financial results for the first half of 2021, showing no sales compared to CNY6.87 million in 2020. The net loss was approximately CNY26.74 million, contrasting with a profit of CNY2.74 million from the same period last year, primarily due to a fair value loss on investments. The Company aims to diversify into healthcare and wastewater treatment sectors, having invested in Shanghai Onway. Cash balance stood at CNY32.54 million as of June 30, 2021, while net cash from financing activities was CNY34.90 million.
China Natural Resources, Inc. (NASDAQ: CHNR) has announced its acquisition of Precise Space-Time Technology Limited for approximately 104.1 million Chinese Yuan (US$16.1 million), representing a 20% discount based on independent valuation. The purchase includes 120 million shares of Feishang Anthracite Resources and three million restricted shares of CHNR. Precise Space-Time Technology holds a 51% stake in Shanghai Onway, a company engaged in rural wastewater treatment in China. This strategic move aims to enhance CHNR's sustainability efforts, aligning with its goals in mining and healthcare sectors while contributing to local environmental solutions.
China Natural Resources (NASDAQ: CHNR) reported its operational results for 2020, showcasing a significant recovery with earnings of CNY 0.90 per share, up from a loss of CNY 0.23 per share in 2019. The company faced challenges due to the COVID-19 pandemic, impacting its strategic diversification into healthcare. In January 2021, CHNR completed a private placement raising US$7.3 million, enhancing its balance sheet.
The firm acquired an 8.7% stake in Feishang Anthracite Resources, aiming to leverage growth opportunities in coal production. Leadership changes in healthcare signal a commitment to diversifying beyond natural resources.
China Natural Resources, Inc. (NASDAQ: CHNR) has appointed Dr. Peng Wenlie as Vice President, effective March 22, 2021. With over 20 years of experience in the pharmaceutical industry, Dr. Peng will focus on evaluating investment opportunities in healthcare and biomedicine. Chairman Wong Wah On Edward expressed enthusiasm for Dr. Peng’s addition, highlighting the potential to diversify the company’s portfolio in the Chinese healthcare market. The company is actively conducting due diligence to identify promising business opportunities beyond natural resources.
CHINA NATURAL RESOURCES, INC. (NASDAQ: CHNR) has successfully closed a registered direct offering totaling $7.3 million on January 22, 2021, issuing approximately 3,960,000 common shares at $1.85 per share. Additionally, in a concurrent private placement, warrants for 1,584,000 common shares at $2.35 each were issued, valid for 36 months. The proceeds will support general corporate purposes. The offering was facilitated by FT Global Capital, Inc.
China Natural Resources, Inc. (NASDAQ: CHNR) has entered into a securities purchase agreement for a registered direct placement of approximately $7.3 million of common shares at $1.85 per share. The issuance will involve 3,960,000 common shares and warrants for up to 1,584,000 additional shares at an exercise price of $2.35. Proceeds will be allocated for general working capital. This transaction is expected to close around January 22, 2021, pending customary conditions.
China Natural Resources, Inc. (NASDAQ: CHNR) announced the appointment of Zou Yu as Vice President, effective October 22, 2020. Zou brings over 10 years of experience in the healthcare sector, having previously served as the general manager of Feishang Enterprise Group's investment management center, where he managed projects worth approximately 800 million Chinese Yuan. His expertise includes mergers and acquisitions exceeding 3 billion Chinese Yuan. This leadership change aims to strengthen the company's exploration of new opportunities within the healthcare sector.